# Dan Theodorescu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6562935/publications.pdf

Version: 2024-02-01

| 226 | 18,456 | 18887 64 | 16186 128 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 230 | 230 | 230 | 29457 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGFÎ² Activity. Molecular Cancer Research, 2022, 20, 637-649. | 1.5 | 4 |
| 2 | Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. Cancer Research, 2022, 82, 1128-1139. | 0.4 | 11 |
| 3 | Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients.. Journal of Clinical Oncology, 2022, 40, 527-527. | 0.8 | 0 |
| 4 | SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.. Journal of Clinical Oncology, 2022, 40, 536-536. | 0.8 | 4 |
| 5 | Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nature Communications, 2022, 13, 1487. | 5.8 | 17 |
| 6 | FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. , 2022, 10, e003939. | | 8 |
| 7 | Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314. European Urology Focus, 2022, , . | 1.6 | 2 |
| 8 | Sex differences in bladder cancer: emerging data and call to action. Nature Reviews Urology, 2022, 19, 447-449. | 1.9 | 7 |
| 9 | Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 410.e19-410.e27. | 0.8 | 7 |
| 10 | Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers.. Journal of Clinical Oncology, 2022, 40, 3017-3017. | 0.8 | 0 |
| 11 | The origin of bladder cancer from mucosal field effects. IScience, 2022, 25, 104551. | 1.9 | 12 |
| 12 | The dynamic roles of the bladder tumour microenvironment. Nature Reviews Urology, 2022, 19, 515-533. | 1.9 | 24 |
| 13 | The Molecular Twin platform: a novel machine learning tool for democratization of precision cancer medicine.. Journal of Clinical Oncology, 2022, 40, e13546-e13546. | 0.8 | 0 |
| 14 | Sex-biased adaptive immune regulation in cancer development and therapy. IScience, 2022, 25, 104717. | 1.9 | 10 |
| 15 | Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors. Bladder Cancer, 2022, 8, 241-254. | 0.2 | 5 |
| 16 | Advances in bladder cancer biology and therapy. Nature Reviews Cancer, 2021, 21, 104-121. | 12.8 | 320 |
| 17 | A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research, 2021, 27, 2435-2441. | 3.2 | 46 |
| 18 | Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 2800. | 1.8 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Androgen Receptor Regulates CD44 Expression in Bladder Cancer. Cancer Research, 2021, 81, 2833-2846. | 0.4 | 27 |
| 20 | The impact of the social construct of race on outcomes among bacille Calmetteâ€GuÃ©rinâ€treated patients with highâ€risk nonâ€muscleâ€“invasive bladder cancer in an equalâ€access setting. Cancer, 2021, 127, 3998-4005. | 2.0 | 3 |
| 21 | Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer. Expert Review of Clinical Pharmacology, 2021, 14, 1345-1352. | 1.3 | 5 |
| 22 | Abstract 614: Transcriptomic analysis of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG-failure. , 2021, , . | | 0 |
| 23 | An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nature Communications, 2021, 12, 4906. | 5.8 | 67 |
| 24 | Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancers, 2021, 13, 4891. | 1.7 | 21 |
| 25 | Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. OncoTargets and Therapy, 2021, Volume 14, 4819-4832. | 1.0 | 11 |
| 26 | TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 24 |
| 27 | Abstract P177: NPEPPS regulates cisplatin-resistance and can be targeted to overcome treatment resistance in patient-derived bladder cancer tumoroids. , 2021, , . | | 0 |
| 28 | Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201. | 1.9 | 18 |
| 29 | Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Communications Biology, 2020, 3, 720. | 2.0 | 82 |
| 30 | Determinants of Resistance to Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 1594. | 1.8 | 39 |
| 31 | Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1. Bladder Cancer, 2019, 5, 131-145. | 0.2 | 11 |
| 32 | Re: Genomic Differences Between â€œPrimaryâ€•and â€œSecondaryâ€•Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 694. | 0.9 | 1 |
| 33 | Targeting DDR2 enhances tumor response to antiâ€“PD-1 immunotherapy. Science Advances, 2019, 5, eaav2437. | 4.7 | 92 |
| 34 | Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice. Carcinogenesis, 2019, 40, 194-201. | 1.3 | 2 |
| 35 | A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene, 2018, 37, 1911-1925. | 2.6 | 102 |
| 36 | Two methods of prediction signatures. Nature Reviews Urology, 2018, 15, 340-342. | 1.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Molecular Cancer Research, 2018, 16, 69-77. | 1.5 | 33 |
| 38 | RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. Pharmacological Reviews, 2018, 70, 1-11. | 7.1 | 78 |
| 39 | Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nature Reviews Urology, 2018, 15, 92-111. | 1.9 | 139 |
| 40 | A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer, 2018, 4, S1-S43. | 0.2 | 0 |
| 41 | A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer, 2018, 4, 269-282. | 0.2 | 6 |
| 42 | Systematic Review: Characteristics andÂPreclinical Uses of Bladder Cancer CellÂLines. Bladder Cancer, 2018, 4, 169-183. | 0.2 | 58 |
| 43 | Metastatic cells are preferentially vulnerable to lysosomal inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8479-E8488. | 3.3 | 38 |
| 44 | RalA controls glucose homeostasis by regulating glucose uptake in brown fat. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7819-7824. | 3.3 | 36 |
| 45 | Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. Oncotarget, 2018, 9, 16718-16730. | 0.8 | 10 |
| 46 | Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach. American Journal of Physiology - Cell Physiology, 2017, 312, C527-C536. | 2.1 | 21 |
| 47 | Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. Pharmacogenomics, 2017, 18, 1167-1178. | 0.6 | 7 |
| 48 | Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. Cancer Research, 2017, 77, 4858-4867. | 0.4 | 19 |
| 49 | New Sister Journal Kidney Cancer. Bladder Cancer, 2017, 3, 143-143. | 0.2 | 0 |
| 50 | The Role of Transcription Factor YY1 in the Biology of Cancer. Critical Reviews in Oncogenesis, 2017, 22, 13-21. | 0.2 | 12 |
| 51 | CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). BMC Cancer, 2016, 16, 713. | 1.1 | 20 |
| 52 | Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clinical Cancer Research, 2016, 22, 4077-4086. | 3.2 | 90 |
| 53 | High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing. Journal of Molecular Medicine, 2016, 94, 1015-1024. | 1.7 | 7 |
| 54 | An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell, 2016, 30, 432-443. | 7.7 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Synthesis of novel Ral inhibitors: An in vitro and in vivo study. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5815-5818. | 1.0 | 12 |
| 56 | GON4L Drives Cancer Growth through a YY1â€“Androgen Receptorâ€“CD24 Axis. Cancer Research, 2016, 76, 5175-5185. | 0.4 | 36 |
| 57 | Pharmacogenomics. Urologic Clinics of North America, 2016, 43, 77-86. | 0.8 | 9 |
| 58 | Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clinical Cancer Research, 2016, 22, 1274-1283. | 3.2 | 25 |
| 59 | CD44: A metastasis driver and therapeutic target. Oncoscience, 2016, 3, 320-321. | 0.9 | 11 |
| 60 | A whole-genome RNAi screen uncovers a novel role for human potassium channels in cell killing by the parasite Entamoeba histolytica. Scientific Reports, 2015, 5, 13613. | 1.6 | 27 |
| 61 | Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. Assay and Drug Development Technologies, 2015, 13, 623-627. | 0.6 | 3 |
| 62 | The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. Bladder Cancer, 2015, 1, 45-63. | 0.2 | 7 |
| 63 | Targeting glycogen metabolism in bladder cancer. Nature Reviews Urology, 2015, 12, 383-391. | 1.9 | 63 |
| 64 | One step closer to targeting RAS. Cell Cycle, 2015, 14, 287-288. | 1.3 | 1 |
| 65 | TERT promoter mutations and telomerase reactivation in urothelial cancer. Science, 2015, 347, 1006-1010. | 6.0 | 255 |
| 66 | The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacologica Sinica, 2015, 36, 291-297. | 2.8 | 30 |
| 67 | RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Molecular Cancer Research, 2015, 13, 483-492. | 1.5 | 18 |
| 68 | A Rho GDP Dissociation Inhibitor Produced by Apoptotic T-Cells Inhibits Growth of Mycobacterium tuberculosis. PLoS Pathogens, 2015, 11, e1004617. | 2.1 | 11 |
| 69 | Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors. Molecular Cancer Research, 2015, 13, 1306-1315. | 1.5 | 24 |
| 70 | Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 53-64. | 0.8 | 11 |
| 71 | Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes and Development, 2015, 29, 2219-2224. | 2.7 | 168 |
| 72 | Drugging the Ral GTPase. Small GTPases, 2015, 6, 157-159. | 0.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Altered Expression of Transmembrane Mucins, MUC1 and MUC4, in Bladder Cancer: Pathological Implications in Diagnosis. PLoS ONE, 2014, 9, e92742. | 1.1 | 39 |
| 74 | Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24. | 5.8 | 3,665 |
| 75 | Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1108-1115. | 0.8 | 24 |
| 76 | The multiMiR R package and database: integration of microRNAâ€“target interactions along with their disease and drug associations. Nucleic Acids Research, 2014, 42, e133-e133. | 6.5 | 409 |
| 77 | Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. Journal of Proteomics, 2014, 98, 44-58. | 1.2 | 64 |
| 78 | Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease. Journal of the National Cancer Institute, 2014, 106, . | 3.0 | 38 |
| 79 | A Cell of Origin Gene Signature Indicates Human Bladder Cancer Has Distinct Cellular Progenitors. Stem Cells, 2014, 32, 974-982. | 1.4 | 40 |
| 80 | Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. Cancer Research, 2014, 74, 5758-5771. | 0.4 | 237 |
| 81 | Discovery and characterization of small molecules that target the GTPase Ral. Nature, 2014, 515, 443-447. | 13.7 | 126 |
| 82 | Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer. Clinical Cancer Research, 2014, 20, 4935-4948. | 3.2 | 101 |
| 83 | Telomerase in Bladder Cancer: Back to a Better Future?. European Urology, 2014, 65, 370-371. | 0.9 | 9 |
| 84 | Re: Phase II Trial of Cetuximab with or Without Paclitaxel in Patients with Advanced Urothelial Tract Carcinoma. European Urology, 2014, 65, 501. | 0.9 | 1 |
| 85 | Pharmacogenomics in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 16-22. | 0.8 | 15 |
| 86 | Robust Prognostic Gene Expression Signatures in Bladder Cancer and Lung Adenocarcinoma Depend on Cell Cycle Related Genes. PLoS ONE, 2014, 9, e85249. | 1.1 | 26 |
| 87 | Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer. PLoS ONE, 2014, 9, e86532. | 1.1 | 13 |
| 88 | Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genetics, 2013, 45, 1459-1463. | 9.4 | 400 |
| 89 | Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics, 2013, 45, 1428-1430. | 9.4 | 164 |
| 90 | TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026. | 3.3 | 1,202 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinomaâ€"Neoadjuvant and Adjuvant Settings. European Urology, 2013, 63, 58-66. | 0.9 | 151 |
| 92 | Clinical opportunities and challenges in targeting tumour dormancy. Nature Reviews Clinical Oncology, 2013, 10, 41-51. | 12.5 | 59 |
| 93 | Translation Initiation Factor eIF3b Expression in Human Cancer and Its Role in Tumor Growth and Lung Colonization. Clinical Cancer Research, 2013, 19, 2850-2860. | 3.2 | 66 |
| 94 | Contributions of KRAS and RAL in Nonâ€"Small-Cell Lung Cancer Growth and Progression. Journal of Thoracic Oncology, 2013, 8, 1492-1501. | 0.5 | 39 |
| 95 | A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness. PLoS ONE, 2013, 8, e53328. | 1.1 | 22 |
| 96 | Transcriptional Signatures of Ral GTPase Are Associated with Aggressive Clinicopathologic Characteristics in Human Cancer. Cancer Research, 2012, 72, 3480-3491. | 0.4 | 36 |
| 97 | Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors. Journal of Immunology, 2012, 188, 198-205. | 0.4 | 170 |
| 98 | RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. OncoImmunology, 2012, 1, 1175-1177. | 2.1 | 35 |
| 99 | CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3588-96. | 3.3 | 79 |
| 100 | CD24 Is an Effector of HIF-1â€"Driven Primary Tumor Growth and Metastasis. Cancer Research, 2012, 72, 5600-5612. | 0.4 | 115 |
| 101 | RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. Journal of Clinical Investigation, 2012, 122, 1503-1518. | 3.9 | 133 |
| 102 | Permissive role of endothelin receptors in tumor metastasis. Life Sciences, 2012, 91, 522-527. | 2.0 | 24 |
| 103 | Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. Life Sciences, 2012, 91, 528-539. | 2.0 | 76 |
| 104 | The faces and friends of RhoGDI2. Cancer and Metastasis Reviews, 2012, 31, 519-528. | 2.7 | 26 |
| 105 | Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation. PLoS ONE, 2012, 7, e36669. | 1.1 | 81 |
| 106 | Re: Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. European Urology, 2012, 62, 183-184. | 0.9 | 0 |
| 107 | Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance. PLoS ONE, 2012, 7, e30550. | 1.1 | 95 |
| 108 | Cyclophilin B Expression Is Associated with In Vitro Radioresistance and Clinical Outcome after Radiotherapy. Neoplasia, 2011, 13, 1122-IN14. | 2.3 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Use of Yeast Chemigenomics and COXEN Informatics in Preclinical Evaluation of Anticancer Agents. Neoplasia, 2011, 13, 72-IN19. | 2.3 | 27 |
| 110 | Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genetics, 2011, 43, 875-878. | 9.4 | 638 |
| 111 | RREB1 Transcription Factor Splice Variants in Urologic Cancer. American Journal of Pathology, 2011, 179, 477-486. | 1.9 | 28 |
| 112 | Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. Journal of Clinical Investigation, 2011, 121, 132-147. | 3.9 | 92 |
| 113 | A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncology, The, 2011, 12, 137-143. | 5.1 | 138 |
| 114 | Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Current Opinion in Urology, 2011, 21, 420-427. | 0.9 | 41 |
| 115 | In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. Journal of Theoretical Biology, 2011, 290, 27-36. | 0.8 | 30 |
| 116 | CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization. Cancer Research, 2011, 71, 3802-3811. | 0.4 | 106 |
| 117 | Genetic testing for metastasis: potential for improved cancer treatment. Future Oncology, 2011, 7, 697-701. | 1.1 | 0 |
| 118 | A Framework to Select Clinically Relevant Cancer Cell Lines for Investigation by Establishing Their Molecular Similarity with Primary Human Cancers. Cancer Research, 2011, 71, 7398-7409. | 0.4 | 22 |
| 119 | Src and Caveolin-1 Reciprocally Regulate Metastasis via a Common Downstream Signaling Pathway in Bladder Cancer. Cancer Research, 2011, 71, 832-841. | 0.4 | 88 |
| 120 | Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunology, Immunotherapy, 2010, 59, 465-72. | 2.0 | 52 |
| 121 | The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU International, 2010, 106, 1477-1483. | 1.3 | 28 |
| 122 | The COXEN Principle: Translating Signatures of In vitro Chemosensitivity into Tools for Clinical Outcome Prediction and Drug Discovery in Cancer. Cancer Research, 2010, 70, 1753-1758. | 0.4 | 105 |
| 123 | Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research, 2010, 16, 711-718. | 3.2 | 72 |
| 124 | Phosphorylation of RalB Is Important for Bladder Cancer Cell Growth and Metastasis. Cancer Research, 2010, 70, 8760-8769. | 0.4 | 55 |
| 125 | RalBP1 Is Necessary for Metastasis of Human Cancer Cell Lines. Neoplasia, 2010, 12, 1003-1012. | 2.3 | 57 |
| 126 | Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma. American Journal of Pathology, 2010, 176, 3062-3072. | 1.9 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437. | 2.5 | 434 |
| 128 | Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Science Translational Medicine, 2010, 2, 46ps42. | 5.8 | 273 |
| 129 | IL10 Personalized Medicine and Drug Discovery in Urological Cancer. Japanese Journal of Urology, 2010, 101, 59. | 0.0 | 0 |
| 130 | A gene expression ratio-based diagnostic test for bladder cancer. Advances and Applications in Bioinformatics and Chemistry, 2009, 2, 17. | 1.6 | 8 |
| 131 | Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5807-5812. | 3.3 | 68 |
| 132 | Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic Therapy. Cancer Research, 2009, 69, 8302-8309. | 0.4 | 80 |
| 133 | Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model. Molecular Cancer Therapeutics, 2009, 8, 2470-2477. | 1.9 | 46 |
| 134 | Rho GDP Dissociation Inhibitor 2 Suppresses Metastasis via Unconventional Regulation of RhoGTPases. Cancer Research, 2009, 69, 2838-2844. | 0.4 | 67 |
| 135 | Bladder Cancer: Narrowing the Gap Between Evidence and Practice. Journal of Clinical Oncology, 2009, 27, 5680-5684. | 0.8 | 56 |
| 136 | Preclinical Drug Development Must Consider the Impact on Metastasis. Clinical Cancer Research, 2009, 15, 4529-4530. | 3.2 | 34 |
| 137 | Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics. Clinical Cancer Research, 2009, 15, 4935-4943. | 3.2 | 97 |
| 138 | Pathways of metastasis suppression in bladder cancer. Cancer and Metastasis Reviews, 2009, 28, 327-333. | 2.7 | 22 |
| 139 | Learning therapeutic lessons from metastasis suppressor proteins. Nature Reviews Cancer, 2009, 9, 253-264. | 12.8 | 162 |
| 140 | The Ral GTPase pathway in metastatic bladder cancer: Key mediator and therapeutic target. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 42-47. | 0.8 | 22 |
| 141 | Utilizing the Molecular Gateway: The Path to Personalized Cancer Management. Clinical Chemistry, 2009, 55, 684-697. | 1.5 | 49 |
| 142 | Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. Molecular and Cellular Proteomics, 2009, 8, 2296-2307. | 2.5 | 100 |
| 143 | Profiling Bladder Cancer Organ Site-Specific Metastasis Identifies LAMC2 as a Novel Biomarker of Hematogenous Dissemination. American Journal of Pathology, 2009, 174, 371-379. | 1.9 | 33 |
| 144 | Genoproteomic Mining of Urothelial Cancer Suggests Î³-Glutamyl Hydrolase and Diazepam-Binding Inhibitor as Putative Urinary Markers of Outcome after Chemotherapy. American Journal of Pathology, 2009, 175, 1824-1830. | 1.9 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Cdc6 and Cyclin E2 Are PTEN-Regulated Genes Associated with Human Prostate Cancer Metastasis. Neoplasia, 2009, 11, 66-76. | 2.3 | 53 |
| 146 | Comparison of Global versus Epidermal Growth Factor Receptor Pathway Profiling for Prediction of Lapatinib Sensitivity in Bladder Cancer. Neoplasia, 2009, 11, 1185-IN20. | 2.3 | 29 |
| 147 | Genomancy: Predicting Tumour Response to Cancer Therapy based on the Oracle Of Genetics. Current Oncology, 2009, 16, 56-58. | 0.9 | 6 |
| 148 | Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World Journal of Urology, 2008, 26, 67-74. | 1.2 | 22 |
| 149 | Discovery and validation of urinary biomarkers for prostate cancer. Proteomics - Clinical Applications, 2008, 2, 556-570. | 0.8 | 133 |
| 150 | Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology, 2008, 5, 206-219. | 4.3 | 300 |
| 151 | Isolation and Identification of Potential Urinary Microparticle Biomarkers of Bladder Cancer. Journal of Proteome Research, 2008, 7, 2088-2096. | 1.8 | 180 |
| 152 | Molecular Credentialing of Rodent Bladder Carcinogenesis Models. Neoplasia, 2008, 10, 838-IN21. | 2.3 | 52 |
| 153 | Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Review of Anticancer Therapy, 2008, 8, 1103-1110. | 1.1 | 16 |
| 154 | Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells. Clinical Cancer Research, 2008, 14, 1478-1486. | 3.2 | 96 |
| 155 | Integrin Agonists as Adjuvants in Chemotherapy for Melanoma. Clinical Cancer Research, 2008, 14, 6193-6197. | 3.2 | 25 |
| 156 | Invasion and Metastasis Models for Studying RhoGDI2 in Bladder Cancer. Methods in Enzymology, 2008, 439, 219-233. | 0.4 | 17 |
| 157 | Family Interactions Among African American Prostate Cancer Survivors. Family and Community Health, 2008, 31, 213-220. | 0.5 | 30 |
| 158 | A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13086-13091. | 3.3 | 284 |
| 159 | Prediction of drug combination chemosensitivity in human bladder cancer. Molecular Cancer Therapeutics, 2007, 6, 578-586. | 1.9 | 46 |
| 160 | Organ-sparing techniques for penile cancer: quo vadis?. Nature Reviews Urology, 2007, 4, 182-183. | 1.4 | 0 |
| 161 | Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer. Clinical Cancer Research, 2007, 13, 3803-3813. | 3.2 | 78 |
| 162 | Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Molecular Cancer Therapeutics, 2007, 6, 1804-1813. | 1.9 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Complementary and Alternative Medicine Modality Use and Beliefs Among African American Prostate Cancer Survivors. Oncology Nursing Forum, 2007, 34, 359-364. | 0.5 | 38 |
| 164 | RhoGDI2: A new metastasis suppressor gene: Discovery and clinical translation. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 401-406. | 0.8 | 36 |
| 165 | A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochemical and Biophysical Research Communications, 2007, 352, 549-555. | 1.0 | 18 |
| 166 | Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). Biochemical and Biophysical Research Communications, 2007, 362, 56-62. | 1.0 | 13 |
| 167 | Rap2 regulates androgen sensitivity in human prostate cancer cells. Prostate, 2007, 67, 1590-1599. | 1.2 | 25 |
| 168 | Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry. Proteomics, 2007, 7, 3681-3692. | 1.3 | 22 |
| 169 | Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?. BJU International, 2007, 99, 780-785. | 1.3 | 7 |
| 170 | Re: Postoperative Nomogram Predicting Risk of Recurrence after Radical Cystectomy for Bladder Cancer. European Urology, 2007, 52, 281-282. | 0.9 | 1 |
| 171 | Mass spectrometry based proteomics in urine biomarker discovery. World Journal of Urology, 2007, 25, 435-443. | 1.2 | 59 |
| 172 | Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncology, The, 2006, 7, 230-240. | 5.1 | 402 |
| 173 | Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clinical Cancer Research, 2006, 12, 3882-3889. | 3.2 | 121 |
| 174 | Robot-Assisted Radical Cystectomy in the Management of Bladder Cancer. Scientific World Journal, The, 2006, 6, 2560-2565. | 0.8 | 8 |
| 175 | Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistance. BJU International, 2006, 98, 1059-1063. | 1.3 | 103 |
| 176 | Status of robotic cystectomy in 2005. World Journal of Urology, 2006, 24, 180-187. | 1.2 | 32 |
| 177 | Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World Journal of Urology, 2006, 24, 565-578. | 1.2 | 10 |
| 178 | Biomarker discovery by CE-MS enables sequence analysisvia MS/MS with platform-independent separation. Electrophoresis, 2006, 27, 2111-2125. | 1.3 | 194 |
| 179 | Does saturation biopsy improve prostate cancer detection?. Nature Reviews Urology, 2006, 3, 468-469. | 1.4 | 2 |
| 180 | The Metastasis-Associated Gene CD24 Is Regulated by Ral GTPase and Is a Mediator of Cell Proliferation and Survival in Human Cancer. Cancer Research, 2006, 66, 1917-1922. | 0.4 | 136 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | The promise of gene-expression analysis in bladder cancer: a clinician's guide. BJU International, 2005, 95, 874-880. | 1.3 | 1 |
| 182 | Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis, 2005, 26, 2797-2808. | 1.3 | 151 |
| 183 | Undetectable prostate specific antigen at 6-12 months. Cancer, 2005, 103, 2499-2506. | 2.0 | 7 |
| 184 | RalA and RalB: Antagonistic Relatives in Cancer Cell Migration. Cancer Research, 2005, 65, 7111-7120. | 0.4 | 118 |
| 185 | Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2. Cancer Research, 2005, 65, 7320-7327. | 0.4 | 105 |
| 186 | Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology, 2005, 65, 1146-1151. | 0.5 | 8 |
| 187 | Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer. Clinical Cancer Research, 2004, 10, 3800-3806. | 3.2 | 155 |
| 188 | Profiling the Evolution of Human Metastatic Bladder Cancer. Cancer Research, 2004, 64, 7813-7821. | 0.4 | 88 |
| 189 | Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer. Clinical Cancer Research, 2004, 10, 8728-8734. | 3.2 | 29 |
| 190 | Health-related quality of life after prostate brachytherapy. BJU International, 2004, 94, 487-491. | 1.3 | 4 |
| 191 | Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. BJU International, 2004, 94, 1003-1009. | 1.3 | 39 |
| 192 | PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene, 2004, 23, 6788-6797. | 2.6 | 78 |
| 193 | Angiogenesis and prostate cancer tumor growth. Journal of Cellular Biochemistry, 2004, 91, 125-150. | 1.2 | 110 |
| 194 | Unusual case of recurrent lowâ€grade invasive and endophytic squamous cell carcinoma of the penis. Scandinavian Journal of Urology and Nephrology, 2004, 38, 258-259. | 1.4 | 2 |
| 195 | Radiation for prostate cancer issue. World Journal of Urology, 2003, 21, 189-189. | 1.2 | 0 |
| 196 | Permanent interstitial brachytherapy for prostate cancer: a current review. World Journal of Urology, 2003, 21, 209-219. | 1.2 | 17 |
| 197 | The Impact of Prostate Volume Following Neoadjuvant Androgen Deprivation on Quality of Life and Voiding Symptoms in Patients Undergoing Permanent Prostate Brachytherapy. European Urology, 2003, 43, 467-472. | 0.9 | 24 |
| 198 | Gene profiling and promoter reporter assays: Novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene, 2003, 22, 1261-1272. | 2.6 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology, 2003, 61, 402-407. | 0.5 | 78 |
| 200 | Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Letters, 2003, 189, 117-128. | 3.2 | 78 |
| 201 | Adrenal Tumor with Caval Extension: Case Report and Review of the Literature. Scandinavian Journal of Urology and Nephrology, 2002, 36, 71-73. | 1.4 | 21 |
| 202 | Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology, 2002, 60, 656-660. | 0.5 | 14 |
| 203 | Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years. Cancer, 2002, 94, 2282-2287. | 2.0 | 97 |
| 204 | The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Research, 2002, 62, 982-5. | 0.4 | 72 |
| 205 | RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Research, 2002, 62, 6418-23. | 0.4 | 185 |
| 206 | Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Research, 2002, 62, 6981-9. | 0.4 | 49 |
| 207 | An 800-kb Region of Deletion at 13q14 in Human Prostate and Other Carcinomas. Genomics, 2001, 77, 135-144. | 1.3 | 29 |
| 208 | Orthotopic Neobladder Following Cystectomy. Journal of Wound, Ostomy and Continence Nursing, 2001, 28, 37-46. | 0.6 | 0 |
| 209 | Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer, 2001, 92, 2095-2101. | 2.0 | 38 |
| 210 | Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer and Metastasis Reviews, 2001, 20, 297-319. | 2.7 | 37 |
| 211 | Cell density mediated pericellular hypoxia leads to induction of HIF-1Î± via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene, 2001, 20, 7624-7634. | 2.6 | 117 |
| 212 | The Role of Vascular Endothelial Growth Factor in the Tissue Specific in Vivo Growth of Prostate Cancer Cells. Growth Factors, 2001, 18, 287-302. | 0.5 | 26 |
| 213 | Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. , 2000, 27, 252-263. | | 69 |
| 214 | The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clinical and Experimental Metastasis, 2000, 18, 519-525. | 1.7 | 117 |
| 215 | Transmembrane Motility Assay of Transiently Transfected Cells by Fluorescent Cell Counting and Luciferase Measurement. BioTechniques, 2000, 29, 81-86. | 0.8 | 27 |
| 216 | Focal Adhesion Kinase, Rap1, and Transcriptional Induction of Vascular Endothelial Growth Factor. Journal of the National Cancer Institute, 2000, 92, 1065-1073. | 3.0 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Prostate tumor progression and prognosis. Urologic Oncology: Seminars and Original Investigations, 2000, 5, 258-264. | 0.8 | 14 |
| 218 | Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology, 2000, 55, 736-742. | 0.5 | 102 |
| 219 | Unusual Case of Non-Exophytic Invasive Penile Squamous Cell Cancer Arising from a Chronic Sinus Tract. Scandinavian Journal of Urology and Nephrology, 1999, 33, 333-335. | 1.4 | 3 |
| 220 | Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approaches. Urology, 1999, 53, 881-890. | 0.5 | 48 |
| 221 | Prognostic markers in localized prostate cancer: from microscopes to molecules. , 1998, 17, 429-437. | | 13 |
| 222 | Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. , 1998, 78, 775-782. | | 40 |
| 223 | Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision. Urology, 1998, 51, 277-282. | 0.5 | 29 |
| 224 | Molecular markers: their role as prognostic indicators for bladder cancer. Current Opinion in Urology, 1997, 7, 282-286. | 0.9 | 2 |
| 225 | Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. International Journal of Cancer, 1991, 49, 938-939. | 2.3 | 64 |
| 226 | Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer and Metastasis Reviews, 1991, 10, 201-215. | 2.7 | 47 |